E I Gusev Selected Research

Cerebrovascular Disorders (Cerebrovascular Occlusion)

1/2015	[Characteristics of risk factors in young and middle-aged patients with first hemispheric ischemic stroke].
1/2005	[Semax in prevention of disease progress and development of exacerbations in patients with cerebrovascular insufficiency].

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

E I Gusev Research Topics

Disease

32	Multiple Sclerosis 01/2017 - 01/2000
19	Ischemic Stroke 01/2022 - 01/2000
16	Stroke (Strokes) 01/2015 - 01/2000
6	Epilepsy (Aura) 01/2008 - 01/2001
5	Relapsing-Remitting Multiple Sclerosis 01/2022 - 01/2002
5	Parkinson Disease (Parkinson's Disease) 01/2020 - 01/2002
3	Nervous System Diseases (Neurological Disorders) 01/2015 - 06/2004
3	Atrophy 01/2013 - 01/2000
2	Seizures (Absence Seizure) 01/2021 - 01/2001
2	Prodromal Symptoms 01/2021 - 01/2020
2	Optic Neuritis (Retrobulbar Neuritis) 01/2018 - 11/2002
2	Inflammation (Inflammations) 01/2015 - 01/2004
2	Cerebrovascular Disorders (Cerebrovascular Occlusion) 01/2015 - 01/2005
2	Demyelinating Diseases (Demyelinating Disease) 01/2015 - 01/2002
2	Neoplasms (Cancer) 01/2015 - 01/2015
2	Necrosis 01/2015 - 10/2002
2	Genetic Predisposition to Disease (Genetic Predisposition) 09/2009 - 08/2003
2	Brain Diseases (Brain Disorder) 03/2007 - 01/2003
2	Hemorrhagic Stroke 01/2007 - 01/2005
2	Movement Disorders (Movement Disorder) 01/2006 - 01/2004
2	Tremor (Tremors) 01/2004 - 01/2002
2	Sclerosis 01/2003 - 01/2002
2	Hypertension (High Blood Pressure) 01/2003 - 01/2002
1	Body Weight (Weight, Body) 01/2022
1	Bradycardia 01/2021
1	Heart Arrest (Cardiac Arrest) 01/2021
1	Consciousness Disorders 01/2021
1	Synucleinopathies 01/2020
1	Cerebral Hemorrhage 01/2019
1	Myocardial Infarction 01/2018
1	Tricuspid Valve Prolapse 01/2015
1	Myocardial Ischemia (Ischemic Heart Diseases) 01/2015
1	Autoimmune Diseases of the Nervous System 01/2015
1	Amyloid Plaque 01/2015
1	Chronic Progressive Multiple Sclerosis 01/2013
1	Ganglion Cysts (Ganglion) 01/2012

Drug/Important Bio-Agent (IBA)

7	InterferonsIBA 01/2022 - 01/2000
6	Interferon beta-1a FDA Link 01/2022 - 01/2003
6	Neuroprotective AgentsIBA 01/2013 - 01/2000
6	Glatiramer Acetate (Copaxone)FDA Link 01/2012 - 01/2002
5	AutoantibodiesIBA 01/2008 - 01/2000
4	Levodopa (L Dopa)FDA LinkGeneric 01/2020 - 01/2004
4	Interferon-betaIBA 01/2011 - 01/2000
4	AntigensIBA 06/2004 - 01/2002
3	Anticonvulsants (Antiepileptic Drugs)IBA 01/2021 - 01/2008
3	Biomarkers (Surrogate Marker)IBA 01/2020 - 01/2002
3	AntibodiesIBA 01/2015 - 04/2001
3	Fibrinogen (Factor I)FDA Link 01/2012 - 01/2008
3	Interferon beta-1b (Betaseron)FDA Link 01/2006 - 01/2000
3	Glutamic Acid (Glutamate)FDA Link 10/2002 - 01/2000
3	Aspartic Acid (Aspartate)FDA Link 10/2002 - 01/2000
3	Glycine (Aminoacetic Acid)FDA LinkGeneric 01/2001 - 01/2000
3	gamma-Aminobutyric Acid (GABA)IBA 01/2001 - 01/2000
2	Tissue Plasminogen Activator (Alteplase)FDA Link 01/2022 - 01/2018
2	Pro-Gly-Pro- ACTH (4-7)IBA 01/2018 - 01/2005
2	cerebrolysinIBA 01/2013 - 01/2007
2	Interleukin-6 (Interleukin 6)IBA 01/2012 - 01/2002
2	Acetates (Acetic Acid Esters)FDA Link 01/2012 - 01/2011
2	CTLA-4 AntigenIBA 11/2011 - 07/2002
2	Betahistine (Serc)IBA 01/2011 - 01/2002
2	SteroidsIBA 01/2006 - 01/2003
2	histochromeIBA 11/2005 - 01/2005
2	Myelin Basic ProteinIBA 11/2003 - 08/2003
2	Heroin (Diamorphine)IBA 01/2003 - 01/2001
2	DNA (Deoxyribonucleic Acid)IBA 01/2003 - 04/2001
2	Mesylates (Mesylate)IBA 01/2003 - 01/2002
2	eprosartan (Teveten)FDA Link 01/2003 - 01/2002
2	HLA-DRB1 Chains (HLA DRB1)IBA 11/2002 - 01/2000
2	Neurotransmitter Agents (Neurotransmitter)IBA 10/2002 - 01/2001
2	Carrier Proteins (Binding Protein)IBA 10/2002 - 01/2000
1	Staphylococcus aureus auR protein (staphylokinase)IBA 01/2022
1	Potassium Channel Blockers (Blockers, Potassium Channel)IBA 01/2021
1	SphingolipidsIBA 01/2021
1	SphingomyelinsIBA 01/2020
1	von Willebrand FactorIBA 01/2019
1	Fibrinolysin FDA Link 01/2018
1	Streptokinase FDA Link 01/2018
1	Brain-Derived Neurotrophic Factor (BDNF)IBA 01/2018
1	Cytokine Receptors (Cytokine Receptor)IBA 01/2016
1	Contrast MediaIBA 01/2015
1	GadoliniumIBA 01/2015
1	HDL LipoproteinsIBA 01/2015
1	Cytostatic AgentsIBA 01/2015
1	Alemtuzumab (Campath)FDA Link 01/2013
1	Monoclonal AntibodiesIBA 01/2013
1	laquinimodIBA 01/2013
1	Biosimilar PharmaceuticalsIBA 01/2013
1	Cytidine Diphosphate Choline (Citicoline)IBA 01/2012
1	antineoplaston A10 (A 10)IBA 01/2012
1	Protons (Proton)IBA 01/2012
1	Retinaldehyde (Retinal)IBA 01/2012
1	CCR5 Receptors (CCR5 Receptor)IBA 11/2011
1	Histocompatibility Antigens Class IIIBA 11/2011
1	Interleukin-7 Receptor alpha SubunitIBA 11/2011

Therapy/Procedure

21	Therapeutics 01/2022 - 01/2000
2	Thrombolytic Therapy 01/2022 - 01/2018
2	Aftercare (After-Treatment) 01/2013 - 01/2005
1	Intramuscular Injections 01/2022
1	Plasmapheresis 01/2015
1	Immunotherapy 11/2011